Movano Health Provides Business Update and Reports First Quarter 2023 Financial Results

About this update from Corvex, Inc.

[{"type":"text","content":"Conference call begins at 9:00 a.m. Pacific time today\nPLEASANTON, Calif., May 15, 2023 /PRNewswire/ -- Today, Movano Health (Nasdaq: MOVE), a purpose-driven healthcare solutions company at the intersection of medical and consumer devices and makers of the Evie Ring, reported financial results for the three months ending March 31, 2023 and provided a business update.\n\n \n \n \n \n \n \n\n \nKey highlights from the first quarter and recent weeks include:\nThe Company announced publicly for the first time that it plans to make the Evie Ring available for purchase in September 2023 for $269 with no subscription. Movano Health's regulatory team continues to make good progress on its 510(k) submission for the Evie Ring's heart rate and blood oxygen saturation (SpO2) data and plans to submit the required documentation to the FDA in June 2023. The Company is prepared to launch the Evie Ring as a wellness device and then transition to a medical device later on if it has not received a decision from the FDA by its planned launch date.In the four months since announcing the Evie Ring at CES in January 2023, the Company has used a combination of organic press and a strategic multi-channel paid and organic social campaign to attract nearly 500,000 website visits and more than 80,000 people have signed up to receive updates about the Evie Ring. The impressive lead list combined with a strong engagement rate on social media is a very positive sign for conversion potential.Movano Health completed its first set of beta programs with four partners, providing the Company with valuable feedback that is being implemented to enhance the Evie Ring user experience.The Company is preparing to commence a second round of beta programs by early July 2023 with a new group of partners, including a global athletic apparel company and two additional leading global medical device companies.As of tomorrow, the Company will have completed a three-week blood pressure clinical trial, which included more than 50 subjects and incorporated for the first time the Company's proprietary radio-frequency (RF) single-chip solution. Movano Health expects to analyze the results of the blood pressure clinical study through the remainder of the second quarter and plans to conduct a glucose clinical trial using the same RF enabled technology in the near future.\"It has only ...

More updates from Corvex, Inc.